In the course of the Neurophagy project, we developed tools and novel methodologies, that go beyond the state of the art and provide new opportunities for the scientific community:
a) We developed a method allowing us to immunopurify mature and intact autophagic vesicles from the mouse brain. This novel method has enabled us to perform proteomic analyses to reveal the brain content of autophagic vesicles. Moreover, it allowed us to study the heterogeneity of brain autophagic vesicles, giving rise to new projects in the lab. For example, we identified vesicles carrying the machinery to fuse with lysosomes and facilitate degradation of their content, but also others that carry a different machinery that allows them to fuse with the plasma membrane and secrete their cargo. The realization of these and possibly other subpopulations of autophagic vesicles will have a great impact in our understanding of how autophagy contributes to brain homeostasis.
b) We developed a method for measuring the autophagic flux in the brain. This method makes use of a previously engineered transgenic mouse line (pCAG::RFP-GFP-LC3), where LC3 is N-terminally tagged with two fluorophores in tandem, RFP and GFP. While GFP is pH sensitive and is quenched in the acidic environment of the lysosome, RFP is pH-insensitive and continues to fluoresce in lysosomes. This mouse was previously used to monitor autophagic flux in peripheral organs, but its use to monitor brain autophagy was hindered by technical challenges. We have developed a method that allows us to preserve fluorescence in the brain. We complemented this achievement with volumetric imaging of different brain areas and subsequent refinement of machine learning tools in IMARIS to ratiometrically analyze the data. As a result, we can now confidently analyze brain autophagic flux in vivo, in multiple brain areas. We have already used this tool to compare the flux in adolescent, adult and aged brains. However, we can envision many applications, for example in neuropathological models where autophagy is suspected to play a role, or under conditions that implicate the brain-body axis.
c) We generated two new mouse lines. The first one is a transgenic mouse allowing us to induce autophagy in a time and cell-time specific manner, and control the duration of the autophagy activation by having the option to terminate it. We are using this mouse to investigate conditions where targeted activation of autophagy in brain cells of choice may be beneficial. The second mouse is a knock-in to generate floxed alleles of Atg101. This gene is involved in the most upstream step of the initiation of biogenesis. Hence, its ablation leads to a complete loss of autophagic structures, as phagophores are not at all formed. This is not the case with existing mouse lines with floxed alleles for atg5 or atg7 which are commonly used in the field to ablate autophagy, but however, leave incomplete phagophore structures behind as they act later in the biogenesis cascade.